These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34380590)

  • 21. Improving detection of cystic fibrosis related liver disease using liver fibrosis assessment tools.
    Scott JA; Jones AM; Jokl E; Gordon-Walker T; Barry PJ; Hanley NA; Piper Hanley K; Athwal VS
    Heliyon; 2023 Nov; 9(11):e21861. PubMed ID: 38053913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver disease in cystic fibrosis.
    Leeuwen L; Fitzgerald DA; Gaskin KJ
    Paediatr Respir Rev; 2014 Mar; 15(1):69-74. PubMed ID: 23769887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current Treatment Options for Cystic Fibrosis-Related Liver Disease.
    Staufer K
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA Sequencing Identifies a Serum MicroRNA Panel, Which Combined With Aspartate Aminotransferase to Platelet Ratio Index Can Detect and Monitor Liver Disease in Pediatric Cystic Fibrosis.
    Calvopina DA; Chatfield MD; Weis A; Coleman MA; Fernandez-Rojo MA; Noble C; Ramm LE; Leung DH; Lewindon PJ; Ramm GA
    Hepatology; 2018 Dec; 68(6):2301-2316. PubMed ID: 30014495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies.
    Dana J; Debray D; Beaufrère A; Hillaire S; Fabre M; Reinhold C; Baumert TF; Berteloot L; Vilgrain V
    J Hepatol; 2022 Feb; 76(2):420-434. PubMed ID: 34678405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cystic fibrosis related liver disease and endocrine considerations.
    Sherwood JS; Ullal J; Kutney K; Hughan KS
    J Clin Transl Endocrinol; 2022 Mar; 27():100283. PubMed ID: 35024343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis.
    Bader RM; Jonas MM; Mitchell PD; Wiggins S; Lee CK
    J Cyst Fibros; 2019 Mar; 18(2):280-285. PubMed ID: 30509601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cystic fibrosis liver disease - from diagnosis to risk factors.
    Ciucă IM; Pop L; Tămaş L; Tăban S
    Rom J Morphol Embryol; 2014; 55(1):91-5. PubMed ID: 24715171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver disease in cystic fibrosis.
    Rowland M; Bourke B
    Curr Opin Pulm Med; 2011 Nov; 17(6):461-6. PubMed ID: 21881510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cystic fibrosis related liver disease--another black box in hepatology.
    Staufer K; Halilbasic E; Trauner M; Kazemi-Shirazi L
    Int J Mol Sci; 2014 Aug; 15(8):13529-49. PubMed ID: 25093717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis.
    Scott J; Jones AM; Piper Hanley K; Athwal VS
    Aliment Pharmacol Ther; 2022 Feb; 55(4):389-400. PubMed ID: 35048397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cystic Fibrosis Liver Disease: Know More.
    Al Sinani S; Al-Mulaabed S; Al Naamani K; Sultan R
    Oman Med J; 2019 Nov; 34(6):482-489. PubMed ID: 31745411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liver disease in cystic fibrosis.
    Kobelska-Dubiel N; Klincewicz B; Cichy W
    Prz Gastroenterol; 2014; 9(3):136-41. PubMed ID: 25097709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease.
    Pereira TN; Lewindon PJ; Smith JL; Murphy TL; Lincoln DJ; Shepherd RW; Ramm GA
    J Hepatol; 2004 Oct; 41(4):576-83. PubMed ID: 15464237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients.
    Boëlle PY; Debray D; Guillot L; Clement A; Corvol H;
    Hepatology; 2019 Apr; 69(4):1648-1656. PubMed ID: 30058245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival Benefits Following Liver Transplantation: A Matched-pair Analysis in Pediatric Patients With Cystic Fibrosis.
    Flemming G; Baumann U; Richter N; Vondran F; Tümmler B; Dittrich AM; Müller C; Vogel M; Pfister ED
    J Pediatr Gastroenterol Nutr; 2021 Sep; 73(3):385-390. PubMed ID: 34091543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores.
    Karlas T; Neuschulz M; Oltmanns A; Güttler A; Petroff D; Wirtz H; Mainz JG; Mössner J; Berg T; Tröltzsch M; Keim V; Wiegand J
    PLoS One; 2012; 7(7):e42139. PubMed ID: 22848732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cystic fibrosis liver disease in Newfoundland and Labrador: a prevalence study.
    Squirell E; Lockyer J
    Can Liver J; 2021; 4(1):33-37. PubMed ID: 35991469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: Results from a prospective longitudinal cohort study.
    Klotter V; Gunchick C; Siemers E; Rath T; Hudel H; Naehrlich L; Roderfeld M; Roeb E
    PLoS One; 2017; 12(6):e0178784. PubMed ID: 28575039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver disease.
    Rath T; Hage L; Kügler M; Menendez Menendez K; Zachoval R; Naehrlich L; Schulz R; Roderfeld M; Roeb E
    PLoS One; 2013; 8(3):e58955. PubMed ID: 23516586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.